News|Articles|August 28, 2024

Tried and True: Exploring Metformin’s Potential for Geographic Atrophy

A new treatment era was born with first-time geographic atrophy approvals in 2023, but many are still searching for the next addition to the treatment landscape.

Across the continuously evolving world of medicine, true breakthroughs remain rare, but when they happen, they can turn a light at the end of the tunnel into a beacon of hope. For patients battling the relentless advance of geographic atrophy (GA), a severe form of age-related macular degeneration (AMD), 2023 marked a game-changing moment as the US Food and Drug Administration (FDA) greenlit not one, but two revolutionary treatments: pegcetacoplan injection (SYFOVRE) and avacincaptad pegol (IZERVAY).^1,2